FDA Brief

Warning letters Drugs

FDA warning letter to

Laboratorio Pharma International SRL

High riskIssued Sep 15, 2021Posted Sep 21, 2021Center for Drug Evaluation and Research | CDER

FDA warns Laboratorio Pharma International over CGMP failures, unapproved GELAZUL, misbranding, and incomplete beta-lactam separation.

What happened

FDA reviewed records the company submitted after a November 6, 2020 request and March 24, 2021 follow-up. The records showed missing specifications and tests for GELAZUL ingredients, inadequate stability data, and insufficient testing of ethyl alcohol for hand sanitizer. FDA also found GELAZUL was an unapproved new drug and misbranded, and that beta-lactam production was not completely separated from other drugs.

What FDA found

  1. The company lacked scientifically sound specifications and finished-product testing, including no menthol specification for GELAZUL and no apparent testing of incoming menthol.

    21 CFR 211.160(b)
  2. The company lacked an adequate stability program to support a three-year expiry and did not provide stability data for hand sanitizer batches.

    21 CFR 211.166(a)
  3. The company failed to test each incoming component for identity, purity, strength, and quality, including testing ethyl alcohol for impurities and identity.

    21 CFR 211.84(d)(2)
  4. GELAZUL Topical Analgesic was an unapproved new drug because it was not generally recognized as safe and effective and did not meet the applicable OTC monograph conditions.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  5. GELAZUL was misbranded because its label lacked a complete domestic address or phone number for serious adverse event reports and did not comply with section 505G marketing requirements.

    FD&C Act sections 502(x) and 502(ee), 21 U.S.C. 352(x), 352(ee)
  6. The company did not establish complete separation between beta-lactam and non-beta-lactam production, including environmental monitoring and personnel flow controls.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA asks the company to respond in writing within 15 working days, describe corrections and preventive actions, and provide a schedule if corrections cannot be completed. If the company wants to make drugs for U.S. distribution in the future, FDA asks it to request a Regulatory Meeting to discuss corrective actions and beta-lactam containment.

Who should pay attention

  • US brands and distributors buying OTC drugs or hand sanitizer from this manufacturer
  • retailers and importers of GELAZUL Topical Analgesic
  • companies relying on beta-lactam/non-beta-lactam contract manufacturing separation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk